<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257841</url>
  </required_header>
  <id_info>
    <org_study_id>2002P-000518SA1</org_study_id>
    <nct_id>NCT01257841</nct_id>
  </id_info>
  <brief_title>Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects</brief_title>
  <official_title>Effects of Four-day Fast on Gut-derived Hormones and Inflammatory Markers in Healthy, Normal-weight Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The original study executed between 2002-2004 was an interventional trial in which 20,
      healthy, normal-weight female subjects were randomized to a four-day fast plus daily
      subcutaneous injections of leptin or a four day fast plus daily subcutaneous injections of a
      placebo. The primary endpoints were gonadotropin pulsatility, TSH secretion and thyroid
      function, and cortisol secretion. The current study is a secondary analysis focussed on the
      placebo group which underwent a four-day fast. The study is looking at the effects of fasting
      on gut-derived hormones and inflammatory markers in healthy, normal-weight women. The
      hypothesis for this secondary analysis was that four days of fasting would augment levels of
      orexigenic gut-derived hormones and suppress levels of anorexigenic gut-derived horomones,
      while suppressing secretion of inflammatory cytokines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hormone levels change from baseline.</measure>
    <time_frame>Change from baseline after 4 days of intervention.</time_frame>
    <description>Original study looking at gonadotropin pulsitility, TSH secretion and thyroid function, and cortisol secretion. Present study looking at gut-hormone secretion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of inflammatory cytokines change from baseline.</measure>
    <time_frame>Change from baseline after 4 days of intervention.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fasting alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasting plus leptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leptin administration</intervention_name>
    <description>Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.</description>
    <arm_group_label>Fasting plus leptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Fasting</intervention_name>
    <description>Complete fasting, save for water and multivitamin, for four days.</description>
    <arm_group_label>Fasting alone</arm_group_label>
    <arm_group_label>Fasting plus leptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female age 18-35

          -  BMI 20-26.0

          -  eumenorrheic with normal FSH, TSH, Prolactin

          -  Hgb &gt; 12 g/dL, normal creatinine

          -  normal puberty and development

          -  negative pregnancy test. In addition, subjects agreed not to be sexually active during
             the course of the inpatient study and to use contraception for a period of 48 hours
             after discharge from the hospital.

        Exclusion Criteria:

          -  medical or endocrine problems known to affect thyroid, reproductive, GH or cortisol
             function

          -  medications known to affect neuroendocrine function

          -  prior history of eating disorder or significant menstrual irregularities

          -  subjects who have a known hypersensitivity to E. Coli derived protein.

          -  subjects with a history of seizure disorder, significant cardiac disease, medication
             for cardiac disease, or kidney disease

          -  history of anaphylaxis or anaphylactoid like reactions.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K Grinspoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Institute of Technology</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Canavan B, Salem RO, Schurgin S, Koutkia P, Lipinska I, Laposata M, Grinspoon S. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab. 2005 Oct;90(10):5779-85. Epub 2005 Aug 2.</citation>
    <PMID>16076944</PMID>
  </results_reference>
  <results_reference>
    <citation>Schurgin S, Canavan B, Koutkia P, Depaoli AM, Grinspoon S. Endocrine and metabolic effects of physiologic r-metHuLeptin administration during acute caloric deprivation in normal-weight women. J Clin Endocrinol Metab. 2004 Nov;89(11):5402-9.</citation>
    <PMID>15531489</PMID>
  </results_reference>
  <results_reference>
    <citation>Koutkia P, Schurgin S, Berry J, Breu J, Lee BS, Klibanski A, Grinspoon S. Reciprocal changes in endogenous ghrelin and growth hormone during fasting in healthy women. Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E814-22. Epub 2005 Jun 21.</citation>
    <PMID>15972272</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2010</study_first_posted>
  <last_update_submitted>December 9, 2010</last_update_submitted>
  <last_update_submitted_qc>December 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Steven K Grinspoon, M.D. Professor of Medicine</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>Fasting</keyword>
  <keyword>Gut hormones</keyword>
  <keyword>Inflammatory Cytokines</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

